| Pair Name | Isoliquiritigenin, Docosahexaenoic acid | ||
| Phytochemical Name | Isoliquiritigenin (PubChem CID: 638278 ) | ||
| Anticancer drug Name | Docosahexaenoic acid (PubChem CID: 445580 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Isoliquiritigenin, Docosahexaenoic acid | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->ROS generation | |||
| Gene Regulation | Up-regulation | Expression | CYCS | hsa54205 |
| Up-regulation | Expression | FAS | hsa355 | |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| Result | Excessive ROS-induced JNK activation and cytochrome c release from mitochondria played a key role in the synergistic anticancer activity of CRC cells by cotreating with DHA and ISL. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Synergistic anticancer effect of docosahexaenoic acid and isoliquiritigenin on human colorectal cancer cells through ROS-mediated regulation of the JNK and cytochrome c release. Mol Biol Rep. 2021 Feb;48(2):1171-1180. doi: 10.1007/s11033-021-06159-6. | Click |
